Dual-target CAR-NK cell therapy for children with neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 21 years old.
- They must have neuroblastoma that has returned, not responded to treatment, or is persistent despite standard therapy.
- Tumor cells must show at least one of the two targets (GD2 or B7-H3) that the therapy attacks.
- They should have had prior standard treatments, including anti-GD2 therapy, unless there's a medical reason not to.
- Your child's overall health must be fairly good (performance score of 50 or above, and life expectancy of at least 8 weeks).
- They must not have any active serious infections, uncontrolled autoimmune or heart/lung/liver/kidney problems, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
This trial is testing a new type of immunotherapy called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has come back or not responded to standard treatment. The goal is to see if these specially engineered cells can find and destroy the cancer cells.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
Hear when a new Relapsed Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.